Price Change to Note: Is Roka Bioscience Inc a Sell? The Stock Declines Again

Price Change to Note: Is Roka Bioscience Inc a Sell? The Stock Declines Again

The stock of Roka Bioscience Inc (NASDAQ:ROKA) is a huge mover today! About 120,938 shares traded hands or 1.19% up from the average. Roka Bioscience Inc (NASDAQ:ROKA) has declined 22.46% since April 27, 2016 and is downtrending. It has underperformed by 27.69% the S&P500.
The move comes after 9 months negative chart setup for the $10.63 million company. It was reported on Nov, 30 by Barchart.com. We have $4.71 PT which if reached, will make NASDAQ:ROKA worth $531,500 less.

Analysts await Roka Bioscience Inc (NASDAQ:ROKA) to report earnings on March, 3.

Roka Bioscience Inc (NASDAQ:ROKA) Ratings Coverage

Out of 3 analysts covering Roka Bioscience (NASDAQ:ROKA), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Roka Bioscience has been the topic of 7 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating by Leerink Swann given on Monday, March 7. The stock has “Hold” rating given by Zacks on Tuesday, September 8. The rating was maintained by Leerink Swann on Friday, August 14 with “Outperform”. The stock has “Hold” rating given by Zacks on Tuesday, August 25.

According to Zacks Investment Research, “Roka Bioscience, Inc. is a molecular diagnostics company. It is focused on developing and commercializing advanced testing solutions for the food safety testing market. Roka provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. Roka Bioscience, Inc. is headquartered in Warren, New Jersey.”

Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.50, from 0.5 in 2016Q1. The ratio increased, as 4 funds sold all Roka Bioscience Inc shares owned while 2 reduced positions. 1 funds bought stakes while 2 increased positions. They now own 11.75 million shares or 4.44% less from 12.30 million shares in 2016Q1.
Renaissance Technologies Ltd Co holds 0% or 55,400 shares in its portfolio. Orbimed Limited Liability Com has 3.22 million shares for 0.02% of their US portfolio. Manufacturers Life Insurance The reported 746 shares or 0% of all its holdings. Drill Craig A has 1.8% invested in the company for 1.60 million shares. Moreover, Wells Fargo Company Mn has 0% invested in Roka Bioscience Inc (NASDAQ:ROKA) for 100 shares. Goldman Sachs Gp holds 0% or 10,577 shares in its portfolio. Bridgeway Capital Mngmt has 207,500 shares for 0% of their US portfolio. Cannell Peter B holds 0% or 58,098 shares in its portfolio. State Bank Of America De accumulated 0% or 4,018 shares. Birchview Capital L P last reported 0.1% of its portfolio in the stock. Blackrock Fund Advisors accumulated 925 shares or 0% of the stock. Blackrock Inc has 120 shares for 0% of their US portfolio. Geode Management Limited Co has invested 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA). Tpg (Sbs) Advsr has 0.02% invested in the company for 2.99 million shares. Tudor Corporation Et Al holds 0% or 32,545 shares in its portfolio.

More notable recent Roka Bioscience Inc (NASDAQ:ROKA) news were published by: Prnewswire.com which released: “Roka Bioscience, Inc. Announces One-For-Ten Reverse Stock Split” on October 11, 2016, also Marketwatch.com with their article: “Roka Bioscience upgraded to outperform from market perform at Leerink Partners” published on July 17, 2014, Prnewswire.com published: “Roka Bioscience, Inc. Prices Private Placement of Preferred Stock and Warrants” on September 16, 2016. More interesting news about Roka Bioscience Inc (NASDAQ:ROKA) were released by: Prnewswire.com and their article: “Roka Bioscience to Co-Present Industry Webinar – Play FDA for a day” published on September 07, 2016 as well as Prnewswire.com‘s news article titled: “Roka Bioscience Reports Second Quarter 2016 Financial Results” with publication date: August 05, 2016.

ROKA Company Profile

Roka Bioscience, Inc., incorporated on September 3, 2009, is a molecular diagnostics company. The Firm is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Firm offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture assays, immunochemical assays and molecular assays. The Firm sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing instrument designed to reduce labor costs and operator error in foodborne pathogen testing laboratories. The Atlas instrument is a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment